The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Heathy Adults

Overview

Información sobre este estudio

The purpose of this study is to better understand the effects of oral nicotinamide riboside (NR) on systemic vascular perfusion in a cohort of healthy adults.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Healthy adult males and females.
  • Between the ages of 40 and 60.
  • Provides consent to participate in the study.
  • Understands and agrees to follow all study procedures and limitations.

Exclusion Criteria:

  • Pregnant, nursing, or trying to conceive.
  • BMI restrictions: < 30.
  • Allergy or sensitivity to study agent ingredients.
  • Hypertension treated with medication.
  • Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study. 
  • Surgery planned during the course of the trial.
  • History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke.
  • History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
  • Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index > 40 kg m^2), or weight stable for at least 3 months prior to enrolling in the study (defined as > 2 kg change in body mass).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/25/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Ryan Hurt, M.D., Ph.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Jennifer Soderlind

(507) 284-4799

Soderlind.Jennifer@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20566391

Mayo Clinic Footer